Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

IPSEN PHARMA GmbH

Home Clinical Trial Sponsors and OrganizationsIPSEN PHARMA GmbH

IPSEN PHARMA GmbH

Einsteinstr. 174, München, Bayern, Germany

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

9

8 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

4

44.4%

Trial Status Distribution

Active, not recruiting

8

88.9%

Completed

1

11.1%

Clinical Trials

Trials sponsored by this organization (9)

Study to investigate the combination of Lanreotide Autogel 120mg and Temozolomid in patients with WITH PROGRESSIVE GASTRO-ENTERO-PANCREATIC NEUROENDOCRINE TUMOURS

Active, not recruiting

Apr 201465 participants

Study to investigate the combination of Lanreotide Autogel 120mg and Temozolomid in patients with WITH PROGRESSIVE GASTRO-ENTERO-PANCREATIC NEUROENDOCRINE TUMOURS

Active, not recruiting

Apr 201465 participants

on-interventional study on the Management of Advanced Prostate Cancer with Triptorelin Pamoate Three Month Formulation (Pamorelin® LA 11.25 mg) or Six Month Formulation (Pamorelin® LA 22.5 mg) with a Focus on Quality of Life, using the PORPUS Questionnaire (Patient-orientated prostate utility scale)

Aug 2011660 participants

The study investigates the new subcutaneous application of Triptorelin pamoate (Pamorelin® LA 11.25 mg) versus the intramuscular application in patients with advanced prostate cancer .

Active, not recruiting

Aug 2010100 participants

Phase II multi-centre, randomised, open, comparative study of the safety and efficacyof transdermal testosterone (Testim®) compared to intramuscular testosteronedepot for the induction of puberty in boys with hypogonadism and delayed puberty - Testim® in delayed puberty

Active, not recruiting

PHASE IIIB, DOUBLE BLIND, PLACEBO CONTROLLED, INTERNATIONAL, MULTICENTER, PARALLEL GROUP STUDY, TO ASSESS THE EFFICACY AND SAFETY OF TESTIM GEL IN COMBINATION WITH A PHOSPHODIESTERASE V INHIBITOR TADALAFIL , IN MALE PATIENTS WITH LOW OR BORDERLINE BASELINE SERUM TESTOSTERONE LEVELS AND ERECTILE DYSFUNCTION - Testimed

Active, not recruiting

Jan 2007264 participants

Phase IIIB, Double Blind, Placebo Controlled, International, Multicenter, Parallel Group Study, to Assess the Efficacy and Safety of Testim Gel in Combination with a Phosphodiesterase V Inhibitor (Tadalafil), in Male Patients with Low or <Borderline> Baseline Serum Testosterone Levels and Erectile Dysfunction - TESTIMED

Active, not recruiting

May 2006264 participants

Phase IIIB, Double Blind, Placebo Controlled, International, Multicenter, Parallel Group Study, to Assess the Efficacy and Safety of Testim Gel in Combination with a Phosphodiesterase V Inhibitor (Tadalafil), in Male Patients with Low or <Borderline> Baseline Serum Testosterone Levels and Erectile Dysfunction - TESTIMED

Active, not recruiting

May 2006264 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials9
Approvals
News

Back to Organizations